<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Neurol.</journal-id>
<journal-title>Frontiers in Neurology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Neurol.</abbrev-journal-title>
<issn pub-type="epub">1664-2295</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fneur.2022.1033327</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neurology</subject>
<subj-group>
<subject>Case Report</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Case report: Recreational nitrous oxide abuse triggered peripheral neuropathy possibly through the immune-mediated pathogenesis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Dong</surname> <given-names>Mei-Xue</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="author-notes" rid="fn002"><sup>&#x02020;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1048770/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Wang</surname> <given-names>Qing</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="author-notes" rid="fn002"><sup>&#x02020;</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Xu</surname> <given-names>Jun-Feng</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="author-notes" rid="fn002"><sup>&#x02020;</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hu</surname> <given-names>Ling</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Yu</surname> <given-names>Ying</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Li</surname> <given-names>Tao</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x0002A;</sup></xref>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Neurology, Renmin Hospital of Wuhan University, Hubei General Hospital</institution>, <addr-line>Wuhan</addr-line>, <country>China</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Neurology, Wuhan No. 9 Hospital</institution>, <addr-line>Wuhan</addr-line>, <country>China</country></aff>
<aff id="aff3"><sup>3</sup><institution>Department of Neurology, Ezhou Central Hospital</institution>, <addr-line>Ezhou</addr-line>, <country>China</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Giovanni Meola, University of Milan, Italy</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Yuan Xue, Shandong Provincial Hospital Affiliated to Shandong First Medical University, China; Jowy Tani, Taipei Medical University, Taiwan</p></fn>
<corresp id="c001">&#x0002A;Correspondence: Tao Li <email>ltll&#x00040;163.com</email></corresp>
<fn fn-type="other" id="fn001"><p>This article was submitted to Neuromuscular Disorders and Peripheral Neuropathies, a section of the journal Frontiers in Neurology</p></fn>
<fn fn-type="equal" id="fn002"><p>&#x02020;These authors have contributed equally to this work</p></fn></author-notes>
<pub-date pub-type="epub">
<day>14</day>
<month>11</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>13</volume>
<elocation-id>1033327</elocation-id>
<history>
<date date-type="received">
<day>31</day>
<month>08</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>23</day>
<month>09</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2022 Dong, Wang, Xu, Hu, Yu and Li.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Dong, Wang, Xu, Hu, Yu and Li</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license> </permissions>
<abstract>
<p>Nitrous oxide (N<sub>2</sub>O), commonly known as laughing gas, is widely used in clinical practice and food industry. However, an increasing number of young people have been abusing N<sub>2</sub>O for recreational purpose, resulting in many functional disorders and sometimes irreversible nerve damage. We present the case of a 20-year-old N<sub>2</sub>O abuser who gradually developed peripheral neuropathy after continuously inhaling N<sub>2</sub>O for 2 months. The neurological symptoms of the patient had kept exacerbation for the next 2 months until she came for medical care sitting in a wheelchair. We suggested the patient halting N<sub>2</sub>O intake and supplementing methylcobalamine according to the standardized protocol. Her symptoms had partly recovered during the following 2 weeks but remained unchanged in another 2 weeks. Antibodies against ganglioside complexes were detected and anti-GM1 IgM antibodies were positive in both cerebrospinal fluid and serum. Intravenous immunoglobulin was given as an additional treatment and the patient&#x00027;s symptoms had significantly recovered further. The patient discharged walking by herself. Then she has been continuously followed up in outpatient department for the next 4 months and taking steroid hormone as well as methylcobalamine. Her symptoms gradually disappeared and all the electrophysiological parameters significantly improved. With this case we were able to show that N<sub>2</sub>O-related peripheral neuropathy is not only a metabolic disorder but also an immune-mediated disease. N<sub>2</sub>O intake can trigger a mimic Guillain-Barr&#x000E9; syndrome.</p></abstract>
<kwd-group>
<kwd>nitrous oxide</kwd>
<kwd>peripheral neuropathy</kwd>
<kwd>ganglioside complexes</kwd>
<kwd>Guillain-Barr&#x000E9; syndrome</kwd>
<kwd>immunoglobin</kwd>
<kwd>steroid hormone</kwd>
</kwd-group>
<counts>
<fig-count count="1"/>
<table-count count="2"/>
<equation-count count="0"/>
<ref-count count="16"/>
<page-count count="6"/>
<word-count count="3565"/>
</counts>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="s1">
<title>Introduction</title>
<p>Nitrous oxide (N<sub>2</sub>O), commonly known as laughing gas, is a colorless, non-irritating gas with a sweetish smell. It is widely used as an anesthetic in clinical practice and can also be easily obtained in the catering industry for whipping cream preparation and in the motor industry as a fuel booster (<xref ref-type="bibr" rid="B1">1</xref>). In the recent years, an increasing number of young people have been abusing N<sub>2</sub>O for recreational purpose. In the UK, N<sub>2</sub>O was the eighth most commonly used substance and its lifetime prevalence was about 38.6% (<xref ref-type="bibr" rid="B2">2</xref>). The N<sub>2</sub>O abuse can cause hypotension, lung injury, apnea, and any other accidental injuries with a large dose in a short time. The chronic toxicities of N<sub>2</sub>O are megaloblastic anemia, psychiatric syndromes and neurological injuries, including subacute combined degeneration, myeloneuropathy, myelopathy and peripheral neuropathy (<xref ref-type="bibr" rid="B3">3</xref>). To date, the mechanism of N<sub>2</sub>O toxicity has not been clearly elucidated and vitamin B12 deficiency is the most extensively studied mechanism. Vitamin B12 is an important cofactor for methionine synthetase and methylmalonyl coenzyme A mutase and its deficiency can lead to a decrease of methionine, tetrahydrofolate, and S-adenosylmethionine, and an increase of homocysteine, 5-methyltetrahydrofolate, and methylmalonic acid, resulting in nerve demyelination and injury (<xref ref-type="bibr" rid="B4">4</xref>). In addition, N<sub>2</sub>O can lead to NMDA antagonism, alteration of cerebral blood flow, and inhibition of the synthesis and release of xanthine and monoamines (<xref ref-type="bibr" rid="B5">5</xref>). Here we present the case of a 20-year-old N<sub>2</sub>O abuser mimicking Guillain-Barr&#x000E9; syndrome (GBS) with significant immune disturbances.</p>
</sec>
<sec id="s2">
<title>Case description</title>
<p>The patient was a 20-year-old camgirl without any other medical history and occasionally inhaled N<sub>2</sub>O for fun in the last 2 years (<xref ref-type="fig" rid="F1">Figure 1A</xref>). She had kept inhaling N<sub>2</sub>O (about 10 whippets daily) after a failed investment 4 months ago. Two months later she gradually felt numbness and weakness in her lower limbs. She didn&#x00027;t pay attention to it and kept inhaling N<sub>2</sub>O without any treatments. The numbness and weakness kept being heavier and her upper limbs also suffered. The superficial sensation had significantly decreased of both hands and legs below knees. She couldn&#x00027;t feed herself with hands (muscular strength: 3/5) nor stand up (proximal muscular strength: 3/5; distal muscular strength: 0/5), and came for medical care sitting in a wheelchair. Her limbs&#x00027; muscular tone had decreased and all the tendon reflexes were disappeared while the overall muscle bulks were normal. The deep sensations of vibration, position, and movement stayed normal. Romberg sign and Babinski sign were negative. She had no defecation problems, psychiatric disorders, headache, epilepsy, cognition impairment, or any other neurological symptoms. She also had no history of vaccine injection, enteritis, or influenza in the last year.</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption><p>Timeline of the case and ELISA results of antibodies against ganglioside complexes. <bold>(A)</bold> The patient started inhaling N<sub>2</sub>O occasionally 2 years ago, felt numbness and weakness 2 months ago, significantly improved after receiving the treatment of IVIG, and almost recovered 6 months after the admission. <bold>(B)</bold> ELISA tests indicated the anti-GM1 IgM antibodies were positive in both CSF and serum while anti-GM1 IgG antibodies were negative. IVIG, intravenous immunoglobulin; CSF, cerebrospinal fluid.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fneur-13-1033327-g0001.tif"/>
</fig>
<p>Blood tests indicated slightly decreased hemoglobin (129 g/L) and increased mean corpuscular volume (97.8 fL). Plasma homocysteine level was significantly elevated (24.67 &#x003BC;mol/L) while the serum levels of folic acid, vitamin B12, and any other vitamins were normal. Magnetic resonance imaging hadn&#x00027;t found demyelination or any other abnormal focuses in both brain and spinal cord. Electromyography examination showed extensive peripheral nerve damage, involving motor nerve, sensory nerve, and nerve root. Axonal injuries were especially obvious and nerve damages of the lower limbs were significant heavier than that of upper limbs (<xref ref-type="table" rid="T1">Table 1</xref>).</p>
<table-wrap position="float" id="T1">
<label>Table 1</label>
<caption><p>Electrophysiological parameters of the case before the treatment with intravenous immunoglobulin.</p></caption>
<table frame="hsides" rules="groups">
<thead><tr>
<th valign="top" align="left"><bold>Motor nerve</bold></th>
<th valign="top" align="left"><bold>Segment</bold></th>
<th valign="top" align="center"><bold>Lat (ms)</bold></th>
<th valign="top" align="center"><bold>Amp (mV)</bold></th>
<th valign="top" align="center"><bold>CV (m/s)</bold></th>
<th valign="top" align="center"><bold>Dist (mm)</bold></th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Medianus (L)</td>
<td valign="top" align="left">Wrist-APB</td>
<td valign="top" align="center">4.00</td>
<td valign="top" align="center">3.6</td>
<td/>
<td valign="top" align="center">55.0</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">Elbow-Wrist</td>
<td valign="top" align="center">8.75</td>
<td valign="top" align="center">3.6</td>
<td valign="top" align="center">48.4</td>
<td valign="top" align="center">230</td>
</tr>
<tr>
<td valign="top" align="left">Medianus (R)</td>
<td valign="top" align="left">Wrist-APB</td>
<td valign="top" align="center">4.29</td>
<td valign="top" align="center">5.1</td>
<td/>
<td valign="top" align="center">55.0</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">Elbow-Wrist</td>
<td valign="top" align="center">8.92</td>
<td valign="top" align="center">4.7</td>
<td valign="top" align="center">47.5</td>
<td valign="top" align="center">220</td>
</tr>
<tr>
<td valign="top" align="left">Peroneus (L)</td>
<td valign="top" align="left">Ankle-EDB</td>
<td valign="top" align="center">Null</td>
<td valign="top" align="center">Null</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td valign="top" align="left">Fib.head-Ankle</td>
<td valign="top" align="center">Null</td>
<td valign="top" align="center">Null</td>
<td/>
<td/>
</tr>
<tr>
<td valign="top" align="left">Peroneus (R)</td>
<td valign="top" align="left">Ankle-EDB</td>
<td valign="top" align="center">Null</td>
<td valign="top" align="center">Null</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td valign="top" align="left">Fib.head-Ankle</td>
<td valign="top" align="center">Null</td>
<td valign="top" align="center">Null</td>
<td/>
<td/>
</tr>
<tr>
<td valign="top" align="left">Tibialis (L)</td>
<td valign="top" align="left">Ankle-Abd hal</td>
<td valign="top" align="center">Null</td>
<td valign="top" align="center">Null</td>
<td/>
<td/>
</tr>
<tr>
<td valign="top" align="left">Tibialis (R)</td>
<td valign="top" align="left">Ankle-Abd hal</td>
<td valign="top" align="center">Null</td>
<td valign="top" align="center">Null</td>
<td/>
<td/>
</tr>
<tr>
<td valign="top" align="left">Ulnaris (L)</td>
<td valign="top" align="left">Wrist-ADM</td>
<td valign="top" align="center">3.23</td>
<td valign="top" align="center">4.4</td>
<td/>
<td valign="top" align="center">55.0</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">Elbow-Wrist</td>
<td valign="top" align="center">7.31</td>
<td valign="top" align="center">4.9</td>
<td valign="top" align="center">52.7</td>
<td valign="top" align="center">215</td>
</tr>
<tr>
<td valign="top" align="left">Ulnaris (R)</td>
<td valign="top" align="left">Wrist-ADM</td>
<td valign="top" align="center">3.05</td>
<td valign="top" align="center">5.0</td>
<td/>
<td valign="top" align="center">55.0</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">Elbow-Wrist</td>
<td valign="top" align="center">6.79</td>
<td valign="top" align="center">5.3</td>
<td valign="top" align="center">56.1</td>
<td valign="top" align="center">210</td>
</tr>
<tr style="border-top: thin solid #000000;">
<td valign="top" align="left"><bold>Sensory nerve</bold></td>
<td valign="top" align="left"><bold>Segment</bold></td>
<td valign="top" align="center"><bold>Peak lat (ms)</bold></td>
<td valign="top" align="center"><bold>Amp (uV)</bold></td>
<td valign="top" align="center"><bold>CV (m/s)</bold></td>
<td valign="top" align="center"><bold>Dist (mm)</bold></td>
</tr>
<tr style="border-top: thin solid #000000;">
<td valign="top" align="left">Medianus (L)</td>
<td valign="top" align="left">Wrist-Dig II</td>
<td valign="top" align="center">2.35</td>
<td valign="top" align="center">27.0</td>
<td valign="top" align="center">48.9</td>
<td valign="top" align="center">115</td>
</tr>
<tr>
<td valign="top" align="left">Medianus (R)</td>
<td valign="top" align="left">Wrist-Dig II</td>
<td valign="top" align="center">2.64</td>
<td valign="top" align="center">22.3</td>
<td valign="top" align="center">47.3</td>
<td valign="top" align="center">125</td>
</tr>
<tr>
<td valign="top" align="left">Radialis (L)</td>
<td valign="top" align="left">EPL tendon-Wrist</td>
<td valign="top" align="center">1.65</td>
<td valign="top" align="center">20.9</td>
<td valign="top" align="center">54.5</td>
<td valign="top" align="center">90.0</td>
</tr>
<tr>
<td valign="top" align="left">Radialis (R)</td>
<td valign="top" align="left">EPL tendon-Wrist</td>
<td valign="top" align="center">1.50</td>
<td valign="top" align="center">20.9</td>
<td valign="top" align="center">66.7</td>
<td valign="top" align="center">100</td>
</tr>
<tr>
<td valign="top" align="left">Superficial peroneal (L)</td>
<td valign="top" align="left">Lower leg-Ankle</td>
<td valign="top" align="center">2.56</td>
<td valign="top" align="center">3.9</td>
<td valign="top" align="center">35.2</td>
<td valign="top" align="center">90.0</td>
</tr>
<tr>
<td valign="top" align="left">Superficial Peroneal (R)</td>
<td valign="top" align="left">Lower leg-Ankle</td>
<td valign="top" align="center">2.64</td>
<td valign="top" align="center">5.4</td>
<td valign="top" align="center">36.0</td>
<td valign="top" align="center">95.0</td>
</tr>
<tr>
<td valign="top" align="left">Suralis (L)</td>
<td valign="top" align="left">Mid.lower leg-Lat.Malleolus</td>
<td valign="top" align="center">2.19</td>
<td valign="top" align="center">4.4</td>
<td valign="top" align="center">38.8</td>
<td valign="top" align="center">85.0</td>
</tr>
<tr>
<td valign="top" align="left">Suralis (R)</td>
<td valign="top" align="left">Mid.lower leg-Lat.Malleolus</td>
<td valign="top" align="center">2.07</td>
<td valign="top" align="center">3.7</td>
<td valign="top" align="center">38.6</td>
<td valign="top" align="center">80.0</td>
</tr>
<tr>
<td valign="top" align="left">Ulnaris (L)</td>
<td valign="top" align="left">Wrist-Dig V</td>
<td valign="top" align="center">1.98</td>
<td valign="top" align="center">24.3</td>
<td valign="top" align="center">48.0</td>
<td valign="top" align="center">95.0</td>
</tr>
<tr>
<td valign="top" align="left">Ulnaris (R)</td>
<td valign="top" align="left">Wrist-Dig V</td>
<td valign="top" align="center">2.14</td>
<td valign="top" align="center">26.9</td>
<td valign="top" align="center">49.1</td>
<td valign="top" align="center">105</td>
</tr>
<tr style="border-top: thin solid #000000;">
<td valign="top" align="left"><bold>F wave</bold></td>
<td valign="top" align="left"><bold>Segment</bold></td>
<td valign="top" align="center"><bold>M-Lat (ms)</bold></td>
<td valign="top" align="center"><bold>F-Lat (ms)</bold></td>
<td valign="top" align="center"><bold>Amp (uV)</bold></td>
<td valign="top" align="center"><bold>F (%)</bold></td>
</tr>
<tr style="border-top: thin solid #000000;">
<td valign="top" align="left">Medianus (L)</td>
<td valign="top" align="left">Wrist-APB</td>
<td valign="top" align="center">3.5</td>
<td valign="top" align="center">31.4</td>
<td valign="top" align="center">59.1</td>
<td valign="top" align="center">33.3</td>
</tr>
<tr>
<td valign="top" align="left">Medianus (R)</td>
<td valign="top" align="left">Wrist-APB</td>
<td valign="top" align="center">4.1</td>
<td valign="top" align="center">28.5</td>
<td valign="top" align="center">153</td>
<td valign="top" align="center">73.3</td>
</tr>
<tr>
<td valign="top" align="left">Tibialis (L)</td>
<td valign="top" align="left">Ankle-Abd hal</td>
<td valign="top" align="center">Null</td>
<td valign="top" align="center">Null</td>
<td/>
<td/>
</tr>
<tr>
<td valign="top" align="left">Tibialis (R)</td>
<td valign="top" align="left">Ankle-Abd hal</td>
<td valign="top" align="center">Null</td>
<td valign="top" align="center">Null</td>
<td/>
<td/>
</tr>
<tr>
<td valign="top" align="left">Ulnaris (L)</td>
<td valign="top" align="left">Wrist-ADM</td>
<td valign="top" align="center">2.6</td>
<td valign="top" align="center">30.2</td>
<td valign="top" align="center">156</td>
<td valign="top" align="center">100</td>
</tr>
<tr>
<td valign="top" align="left">Ulnaris (R)</td>
<td valign="top" align="left">Wrist-ADM</td>
<td valign="top" align="center">3.3</td>
<td valign="top" align="center">28.4</td>
<td valign="top" align="center">224</td>
<td valign="top" align="center">100</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>&#x0201C;Null&#x0201D; indicates that no signal can be detected; Lat, latency; ms, millisecond; Amp, amplitude; mV, millivolt; CV, conduction velocity; Dist, distance; L, left; R, right; APB, abductor pollicis brevis; EDB, extensor digitorum brevis; Abd hal, abductor hallucis; Fib.head, fibular head; ADM, abductor digiti minimi; Mid.lower leg, the middle of lower leg; Dig, digitus; EPL, extensor pollicis longus.</p>
</table-wrap-foot>
</table-wrap>
<p>N<sub>2</sub>O-related peripheral neuropathy was diagnosed according to the medical history of N<sub>2</sub>O abuse, typical clinical manifestations, and the above auxiliary examinations. Guillain-Barr&#x000E9; syndrome (especially acute motor axonal neuropathy, AMAN) should also be considered as differential diagnosis. After all, the patient was suggested to halt N<sub>2</sub>O intake and use methylcobalamine for supplementation according to the standardized protocol. The patient&#x00027;s symptoms had partly recovered during the following 2 weeks. The muscular strength of upper limbs increased to 4/5 while superficial sensation and muscular strength of lower limbs recovered slightly. These syndromes remained unchanged after another 2 weeks.</p>
<p>To obtain optimal treatments further, lumbar puncture was performed and cerebrospinal fluid (CSF) was obtained for tests. The leukocyte count of CSF was 3 cells per &#x003BC;l while the protein level was 0.23 g/L. Antibodies against ganglioside complexes were also detected using a commercial ELISA kit and anti-GM1 IgM antibodies were positive in both serum and CSF while anti-GM1 IgG antibodies were negative (<xref ref-type="fig" rid="F1">Figure 1B</xref>). Intravenous immunoglobulin (0.4g/kg &#x000D7; 5 days) was then given as an additional treatment. The patient&#x00027;s symptoms had significantly improved a week later. Her muscular strength of upper limbs and proximal lower limbs increased to 5/5 when the distal lower limbs increased to 1/5. Her superficial sensation had also partly recovered. The patient discharged from the hospital and could walk independently with a steppage gait and take good care of herself.</p>
<p>Then she has been continuously followed up in outpatient department. Considering the amazing treatment outcome of immunoglobin, she accepted the injection of methylprednisolone (1,000 mg qd &#x000D7; 5 days) and orally took prednisone (60 mg qd &#x000D7; 5 days, 30 mg &#x000D7; 5 days, 15 mg qd &#x000D7; 5 days, 10 mg &#x000D7; 5 days) as follows. After that, she has been continuously taking prednisone 5 mg daily. Four months after the discharge from hospital, her numbness gradually disappeared and the muscular strength of distal lower limbs increased to 4/5. Her gait was almost normal and all the electrophysiological parameters significantly improved. The latencies of motor nerves, sensory nerves, and F waves had extensively decreased while the amplitudes had increased. The incidences of F waves also had significantly increased (<xref ref-type="table" rid="T2">Table 2</xref>). The patient and her parents were aware of the whole process and pleased with the treatment outcome in spite of the injury induced by lumbar puncture, high price of immunoglobulin, and potential side effects of prednisone.</p>
<table-wrap position="float" id="T2">
<label>Table 2</label>
<caption><p>Electrophysiological parameters of the case 4 months after the discharge from hospital.</p></caption>
<table frame="hsides" rules="groups">
<thead><tr>
<th valign="top" align="left"><bold>Motor nerve</bold></th>
<th valign="top" align="left"><bold>Segment</bold></th>
<th valign="top" align="center"><bold>Lat (ms)</bold></th>
<th valign="top" align="center"><bold>Amp (mV)</bold></th>
<th valign="top" align="center"><bold>CV (m/s)</bold></th>
<th valign="top" align="center"><bold>Dist (mm)</bold></th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Medianus (L)</td>
<td valign="top" align="left">Wrist-APB</td>
<td valign="top" align="center">3.58</td>
<td valign="top" align="center">7.1</td>
<td/>
<td valign="top" align="center">65.0</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">Elbow-Wrist</td>
<td valign="top" align="center">7.06</td>
<td valign="top" align="center">6.9</td>
<td valign="top" align="center">57.5</td>
<td valign="top" align="center">200</td>
</tr>
<tr>
<td valign="top" align="left">Medianus (R)</td>
<td valign="top" align="left">Wrist-APB</td>
<td valign="top" align="center">3.75</td>
<td valign="top" align="center">8.5</td>
<td/>
<td valign="top" align="center">65.0</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">Elbow-Wrist</td>
<td valign="top" align="center">7.54</td>
<td valign="top" align="center">7.9</td>
<td valign="top" align="center">60.7</td>
<td valign="top" align="center">230</td>
</tr>
<tr>
<td valign="top" align="left">Peroneus (L)</td>
<td valign="top" align="left">Ankle-EDB</td>
<td valign="top" align="center">Null</td>
<td valign="top" align="center">Null</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td valign="top" align="left">Fib.head-Ankle</td>
<td valign="top" align="center">Null</td>
<td valign="top" align="center">Null</td>
<td/>
<td/>
</tr>
<tr>
<td valign="top" align="left">Peroneus (R)</td>
<td valign="top" align="left">Ankle-EDB</td>
<td valign="top" align="center">Null</td>
<td valign="top" align="center">Null</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td valign="top" align="left">Fib.head-Ankle</td>
<td valign="top" align="center">Null</td>
<td valign="top" align="center">Null</td>
<td/>
<td/>
</tr>
<tr>
<td valign="top" align="left">Tibialis (L)</td>
<td valign="top" align="left">Ankle-Abd hal</td>
<td valign="top" align="center">5.37</td>
<td valign="top" align="center">0.082</td>
<td/>
<td valign="top" align="center">70.0</td>
</tr>
<tr>
<td valign="top" align="left">Tibialis (R)</td>
<td valign="top" align="left">Ankle-Abd hal</td>
<td valign="top" align="center">4.74</td>
<td valign="top" align="center">0.22</td>
<td/>
<td valign="top" align="center">70.0</td>
</tr>
<tr>
<td valign="top" align="left">Ulnaris (L)</td>
<td valign="top" align="left">Wrist-ADM</td>
<td valign="top" align="center">2.63</td>
<td valign="top" align="center">7.2</td>
<td/>
<td valign="top" align="center">60.0</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">Elbow-Wrist</td>
<td valign="top" align="center">5.64</td>
<td valign="top" align="center">7.2</td>
<td valign="top" align="center">61.5</td>
<td valign="top" align="center">185</td>
</tr>
<tr>
<td valign="top" align="left">Ulnaris (R)</td>
<td valign="top" align="left">Wrist-ADM</td>
<td valign="top" align="center">2.54</td>
<td valign="top" align="center">10.0</td>
<td/>
<td valign="top" align="center">60.0</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">Elbow-Wrist</td>
<td valign="top" align="center">5.31</td>
<td valign="top" align="center">9.3</td>
<td valign="top" align="center">61.4</td>
<td valign="top" align="center">170</td>
</tr>
<tr style="border-top: thin solid #000000;">
<td valign="top" align="left"><bold>Sensory nerve</bold></td>
<td valign="top" align="left"><bold>Segment</bold></td>
<td valign="top" align="center"><bold>Peak lat (ms)</bold></td>
<td valign="top" align="center"><bold>Amp (uV)</bold></td>
<td valign="top" align="center"><bold>CV (m/s)</bold></td>
<td valign="top" align="center"><bold>Dist (mm)</bold></td>
</tr>
<tr style="border-top: thin solid #000000;">
<td valign="top" align="left">Medianus (L)</td>
<td valign="top" align="left">Wrist-Dig II</td>
<td valign="top" align="center">2.25</td>
<td valign="top" align="center">44.2</td>
<td valign="top" align="center">55.6</td>
<td valign="top" align="center">125</td>
</tr>
<tr>
<td valign="top" align="left">Medianus (R)</td>
<td valign="top" align="left">Wrist-Dig II</td>
<td valign="top" align="center">2.48</td>
<td valign="top" align="center">39.1</td>
<td valign="top" align="center">52.4</td>
<td valign="top" align="center">130</td>
</tr>
<tr>
<td valign="top" align="left">Radialis (L)</td>
<td valign="top" align="left">EPL tendon-Wrist</td>
<td valign="top" align="center">1.51</td>
<td valign="top" align="center">26.7</td>
<td valign="top" align="center">59.6</td>
<td valign="top" align="center">90.0</td>
</tr>
<tr>
<td valign="top" align="left">Radialis (R)</td>
<td valign="top" align="left">EPL tendon-Wrist</td>
<td valign="top" align="center">1.35</td>
<td valign="top" align="center">28.8</td>
<td valign="top" align="center">66.7</td>
<td valign="top" align="center">90.0</td>
</tr>
<tr>
<td valign="top" align="left">Superficial Peroneal (L)</td>
<td valign="top" align="left">Lower leg-Ankle</td>
<td valign="top" align="center">1.73</td>
<td valign="top" align="center">14.5</td>
<td valign="top" align="center">49.1</td>
<td valign="top" align="center">85.0</td>
</tr>
<tr>
<td valign="top" align="left">Superficial Peroneal (R)</td>
<td valign="top" align="left">Lower leg-Ankle</td>
<td valign="top" align="center">1.84</td>
<td valign="top" align="center">13.1</td>
<td valign="top" align="center">43.5</td>
<td valign="top" align="center">80.0</td>
</tr>
<tr>
<td valign="top" align="left">Suralis (L)</td>
<td valign="top" align="left">Mid.lower leg-Lat.Malleolus</td>
<td valign="top" align="center">1.87</td>
<td valign="top" align="center">7.6</td>
<td valign="top" align="center">42.8</td>
<td valign="top" align="center">80.0</td>
</tr>
<tr>
<td valign="top" align="left">Suralis (R)</td>
<td valign="top" align="left">Mid.lower leg-Lat.Malleolus</td>
<td valign="top" align="center">1.66</td>
<td valign="top" align="center">11.7</td>
<td valign="top" align="center">42.2</td>
<td valign="top" align="center">70.0</td>
</tr>
<tr>
<td valign="top" align="left">Ulnaris (L)</td>
<td valign="top" align="left">Wrist-Dig V</td>
<td valign="top" align="center">1.73</td>
<td valign="top" align="center">45.4</td>
<td valign="top" align="center">54.9</td>
<td valign="top" align="center">95.0</td>
</tr>
<tr>
<td valign="top" align="left">Ulnaris (R)</td>
<td valign="top" align="left">Wrist-Dig V</td>
<td valign="top" align="center">1.84</td>
<td valign="top" align="center">43.8</td>
<td valign="top" align="center">59.8</td>
<td valign="top" align="center">110</td>
</tr>
<tr style="border-top: thin solid #000000;">
<td valign="top" align="left"><bold>F wave</bold></td>
<td valign="top" align="left"><bold>Segment</bold></td>
<td valign="top" align="center"><bold>M-Lat (ms)</bold></td>
<td valign="top" align="center"><bold>F-Lat (ms)</bold></td>
<td valign="top" align="center"><bold>Amp (uV)</bold></td>
<td valign="top" align="center"><bold>F (%)</bold></td>
</tr>
<tr style="border-top: thin solid #000000;">
<td valign="top" align="left">Medianus (L)</td>
<td valign="top" align="left">Wrist-APB</td>
<td valign="top" align="center">3.4</td>
<td valign="top" align="center">26.7</td>
<td valign="top" align="center">267</td>
<td valign="top" align="center">76.9</td>
</tr>
<tr>
<td valign="top" align="left">Medianus (R)</td>
<td valign="top" align="left">Wrist-APB</td>
<td valign="top" align="center">3.6</td>
<td valign="top" align="center">26.8</td>
<td valign="top" align="center">463</td>
<td valign="top" align="center">91.7</td>
</tr>
<tr>
<td valign="top" align="left">Tibialis (L)</td>
<td valign="top" align="left">Ankle-Abd hal</td>
<td valign="top" align="center">Null</td>
<td valign="top" align="center">Null</td>
<td/>
<td/>
</tr>
<tr>
<td valign="top" align="left">Tibialis (R)</td>
<td valign="top" align="left">Ankle-Abd hal</td>
<td valign="top" align="center">Null</td>
<td valign="top" align="center">Null</td>
<td/>
<td/>
</tr>
<tr>
<td valign="top" align="left">Ulnaris (L)</td>
<td valign="top" align="left">Wrist-ADM</td>
<td valign="top" align="center">2.5</td>
<td valign="top" align="center">27.3</td>
<td valign="top" align="center">189</td>
<td valign="top" align="center">100</td>
</tr>
<tr>
<td valign="top" align="left">Ulnaris (R)</td>
<td valign="top" align="left">Wrist-ADM</td>
<td valign="top" align="center">2.4</td>
<td valign="top" align="center">25.6</td>
<td valign="top" align="center">185</td>
<td valign="top" align="center">100</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>&#x0201C;Null&#x0201D; indicates that no signal can be detected; Lat, latency; ms, millisecond; Amp, amplitude; mV, millivolt; CV, conduction velocity; Dist, distance; L, left; R, right; APB, abductor pollicis brevis; EDB, extensor digitorum brevis; Abd hal, abductor hallucis; Fib.head, fibular head; ADM, abductor digiti minimi; Mid.lower leg, the middle of lower leg; Dig, digitus; EPL, extensor pollicis longus.</p>
</table-wrap-foot>
</table-wrap></sec>
<sec sec-type="discussion" id="s3">
<title>Discussion</title>
<p>Commonly, recreational N<sub>2</sub>O abuse is recognized to cause metabolic disorders with vitamin B12 deficiency. However, vitamin B12 deficiency is not sufficient to account for N<sub>2</sub>O-induced peripheral neuropathy as these patients showed prominent motor superexcitability changes and less prominent sensory superexcitability changes in nerve excitability test when compared to patients with vitamin B12 deficiency (<xref ref-type="bibr" rid="B6">6</xref>). Here, we present the case of a 20-year-old N<sub>2</sub>O abuser suffering peripheral neuropathy mimicking GBS with immune disturbances.</p>
<p>Peripheral neuropathy is the most common N<sub>2</sub>O-related neurological disorder with a morbidity up to 97% (<xref ref-type="bibr" rid="B7">7</xref>). These patients primarily exhibited limb numbness or weakness, especially the lower limbs. Decreased muscle strength, superficial sensory disturbances, and decreased tendon reflex were the most common neurological signs according to the published report (<xref ref-type="bibr" rid="B7">7</xref>). Increased plasma homocysteine level is more sensitive than plasma vitamin B12 level for clinical diagnosis, as N<sub>2</sub>O mainly consumes vitamin B12 in tissue but not blood (<xref ref-type="bibr" rid="B3">3</xref>). Electromyography of these patients indicated mixed axonal and demyelination injury, including motor and sensory nerves simultaneously. Abnormal F wave and H reflex were also found in the majority of N<sub>2</sub>O abuser (<xref ref-type="bibr" rid="B8">8</xref>). All in all, the case we presented was a typical N<sub>2</sub>O-related peripheral neuropathy according to these characteristics.</p>
<p>However, without the medical history of N<sub>2</sub>O abuse, these patients were usually misdiagnosed as GBS (<xref ref-type="bibr" rid="B9">9</xref>). The absent medical history of vaccine injection, enteritis, or influenza before the onset didn&#x00027;t support the diagnosis of GBS. The course of disease progression of the patient was also significantly longer than the natural history of GBS (2&#x02013;4 weeks). To our knowledge, GBS is more likely to occur in the middle-aged or aged population but not the youth. The electrophysiological features of N<sub>2</sub>O abuser were dramatically different from those in acute inflammatory demyelinating polyradiculoneuropathy (a GBS variant), but exactly similar to another GBS variant (AMAN). It&#x00027;s difficult to differentiate N<sub>2</sub>O abuse and AMAN according to those electrophysiological findings (<xref ref-type="bibr" rid="B10">10</xref>). Meanwhile, the injury severity of lower limbs is usually heavier than the upper limbs in N<sub>2</sub>O abuser while it is similar in patient with GBS (<xref ref-type="bibr" rid="B11">11</xref>). The difference in the distal and proximal compound muscle action potential amplitudes of the upper limbs can be a parameter for differential diagnosis between the N<sub>2</sub>O abuser and AMAN patients, as the axonal injury was more severe in AMAN patients than N<sub>2</sub>O abuser, especially upper limbs (<xref ref-type="bibr" rid="B10">10</xref>). GBS is an immune-mediated disease while N<sub>2</sub>O-related neurological syndromes are deemed as metabolic disorders. Albuminocytologic dissociation and antibodies against ganglioside complexes in CSF were the specific characteristics of GBS. However, the potential pathogenesis seemed to be more complicated as the motor neuropathy of young N<sub>2</sub>O abuser remained disabled with methylcobalamine supplementation in follow-up research (<xref ref-type="bibr" rid="B12">12</xref>).</p>
<p>Here, although the patient was suggested to halt N<sub>2</sub>O intake and supplement methylcobalamine according to the current standardized protocol, her syndromes had only partly recovered without further progress. Lumbar puncture was performed and CSF was tested. Albuminocytologic dissociation was not found in CSF while we were the first to report positive anti-GM1 IgM antibodies in both CSF and serum. Gangliosides are specifically enriched in nervous system plasma membranes while GM1 is mainly expressed at nodes of Ranvier and motor nerve terminals (<xref ref-type="bibr" rid="B13">13</xref>). When GM1 or its mimicry, <italic>Campylobacter jejuni</italic> strains, are exposed to the autoimmune system, anti-GM1 antibodies are produced and activate the complement cascade, leading to either reversible conduction failure or axonal degeneration in AMAN patients (<xref ref-type="bibr" rid="B14">14</xref>). Anti-GM1 IgM antibodies have also been found in multifocal motor neuropathy, autoimmune limbic encephalitis, Bickerstaff brainstem encephalitis, and any other patients with neuronal or glial damage, resulting in the exposure of GM1 to autoimmune system (<xref ref-type="bibr" rid="B15">15</xref>). The disturbed immunological system of the patient with positive anti-GM1 IgM antibodies were probably primarily caused by N<sub>2</sub>O or secondary to the peripheral neuropathy by N<sub>2</sub>O. After all, the favorable prognosis with intravenous immunoglobin and steroid hormone further validated our supposes that immunological system was involved in the N<sub>2</sub>O-related peripheral neuropathy (<xref ref-type="bibr" rid="B12">12</xref>). The effect of N<sub>2</sub>O on the neuroimmune system is possibly through vitamin B12 deficiency or any other unclear pathways to be clarified in future (<xref ref-type="bibr" rid="B16">16</xref>).</p>
</sec>
<sec sec-type="conclusions" id="s4">
<title>Conclusion</title>
<p>With this case we were able to show that recreational N<sub>2</sub>O abuse can cause immune-mediated disorder besides metabolic disorder. N<sub>2</sub>O-related peripheral neuropathy is a mimic of GBS with many similar characteristics. We therefore encouraged all clinicians to perform CSF tests of antibodies against ganglioside complexes when encountering N<sub>2</sub>O abusers. The potential immunological pathogenesis should be clarified to find novel treatments for these patients.</p>
</sec>
<sec sec-type="data-availability" id="s5">
<title>Data availability statement</title>
<p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p>
</sec>
<sec id="s6">
<title>Ethics statement</title>
<p>The studies involving human participants were reviewed and approved by the Local Ethics Committee of Renmin Hospital of Wuhan University. The patients/participants provided their written informed consent to participate in this study.</p>
</sec>
<sec id="s7">
<title>Author contributions</title>
<p>M-XD and TL designed the study and analyzed the patient data. QW, J-FX, LH, and YY collected the original clinical data. M-XD wrote the first draft of the manuscript. All authors commented on previous versions of the manuscript and read and approved the final manuscript.</p>
</sec>
<sec sec-type="funding-information" id="s8">
<title>Funding</title>
<p>This work was supported by the Open Fund of Hubei Key Laboratory of Renmin Hospital of Wuhan University (2021KFY040).</p>
</sec>
<sec sec-type="COI-statement" id="conf1">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s9">
<title>Publisher&#x00027;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</body>
<back>
<sec sec-type="supplementary-material" id="s10">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fneur.2022.1033327/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fneur.2022.1033327/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Image_1.PNG" id="SM1" mimetype="image/png" xmlns:xlink="http://www.w3.org/1999/xlink"/></sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Inquimbert</surname> <given-names>C</given-names></name> <name><surname>Maitre</surname> <given-names>Y</given-names></name> <name><surname>Moulis</surname> <given-names>E</given-names></name> <name><surname>Gremillet</surname> <given-names>V</given-names></name> <name><surname>Tramini</surname> <given-names>P</given-names></name> <name><surname>Valcarcel</surname> <given-names>J</given-names></name> <etal/></person-group>. <article-title>Recreational nitrous oxide use and associated factors among health profession students in France</article-title>. <source>Int J Environ Res Public Health</source>. (<year>2022</year>) <volume>19</volume>:<fpage>5237</fpage>. <pub-id pub-id-type="doi">10.3390/ijerph19095237</pub-id><pub-id pub-id-type="pmid">35564631</pub-id></citation></ref>
<ref id="B2">
<label>2.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaar</surname> <given-names>SJ</given-names></name> <name><surname>Ferris</surname> <given-names>J</given-names></name> <name><surname>Waldron</surname> <given-names>J</given-names></name> <name><surname>Devaney</surname> <given-names>M</given-names></name> <name><surname>Ramsey</surname> <given-names>J</given-names></name> <name><surname>Winstock</surname> <given-names>AR</given-names></name></person-group>. <article-title>Up: the rise of nitrous oxide abuse. An international survey of contemporary nitrous oxide use</article-title>. <source>J Psychopharmacol.</source> (<year>2016</year>) <volume>30</volume>:<fpage>395</fpage>&#x02013;<lpage>401</lpage>. <pub-id pub-id-type="doi">10.1177/0269881116632375</pub-id><pub-id pub-id-type="pmid">26912510</pub-id></citation></ref>
<ref id="B3">
<label>3.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname> <given-names>L</given-names></name> <name><surname>Li</surname> <given-names>Q</given-names></name> <name><surname>Li</surname> <given-names>Q</given-names></name> <name><surname>Chen</surname> <given-names>H</given-names></name> <name><surname>Zhang</surname> <given-names>R</given-names></name> <name><surname>Shi</surname> <given-names>H</given-names></name> <etal/></person-group>. <article-title>Clinical, electrophysiological and radiological features of nitrous oxide-induced neurological disorders</article-title>. <source>Neuropsychiatr Dis Treat.</source> (<year>2020</year>) <volume>16</volume>:<fpage>977</fpage>&#x02013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.2147/NDT.S236939</pub-id><pub-id pub-id-type="pmid">32346292</pub-id></citation></ref>
<ref id="B4">
<label>4.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Largeau</surname> <given-names>B</given-names></name> <name><surname>Karam</surname> <given-names>A</given-names></name> <name><surname>Potey</surname> <given-names>C</given-names></name> <name><surname>Caous</surname> <given-names>AS</given-names></name> <name><surname>Tard</surname> <given-names>C</given-names></name> <name><surname>Carton</surname> <given-names>L</given-names></name> <etal/></person-group>. <article-title>Myeloneuropathy induced by recreational nitrous oxide use with variable exposure levels</article-title>. <source>Eur J Neurol.</source> (<year>2022</year>) <volume>29</volume>:<fpage>2173</fpage>&#x02013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1111/ene.15370</pub-id><pub-id pub-id-type="pmid">35460312</pub-id></citation></ref>
<ref id="B5">
<label>5.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xiang</surname> <given-names>Y</given-names></name> <name><surname>Li</surname> <given-names>L</given-names></name> <name><surname>Ma</surname> <given-names>X</given-names></name> <name><surname>Li</surname> <given-names>S</given-names></name> <name><surname>Xue</surname> <given-names>Y</given-names></name> <name><surname>Yan</surname> <given-names>P</given-names></name> <etal/></person-group>. <article-title>Recreational nitrous oxide abuse: prevalence, neurotoxicity, and treatment</article-title>. <source>Neurotox Res.</source> (<year>2021</year>) <volume>39</volume>:<fpage>975</fpage>&#x02013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1007/s12640-021-00352-y</pub-id><pub-id pub-id-type="pmid">33770366</pub-id></citation></ref>
<ref id="B6">
<label>6.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tani</surname> <given-names>J</given-names></name> <name><surname>Weng</surname> <given-names>HY</given-names></name> <name><surname>Chen</surname> <given-names>HJ</given-names></name> <name><surname>Chang</surname> <given-names>TS</given-names></name> <name><surname>Sung</surname> <given-names>JY</given-names></name> <name><surname>Lin</surname> <given-names>CS</given-names></name> <etal/></person-group>. <article-title>Elucidating unique axonal dysfunction between nitrous oxide abuse and vitamin B12 deficiency</article-title>. <source>Front Neurol.</source> (<year>2019</year>) <volume>10</volume>:<fpage>704</fpage>. <pub-id pub-id-type="doi">10.3389/fneur.2019.00704</pub-id><pub-id pub-id-type="pmid">31354607</pub-id></citation></ref>
<ref id="B7">
<label>7.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>M</given-names></name> <name><surname>Qiao</surname> <given-names>Y</given-names></name> <name><surname>Li</surname> <given-names>W</given-names></name> <name><surname>Fang</surname> <given-names>X</given-names></name> <name><surname>Gao</surname> <given-names>H</given-names></name> <name><surname>Zheng</surname> <given-names>D</given-names></name> <etal/></person-group>. <article-title>Analysis of clinical characteristics and prognostic factors in 110 patients with nitrous oxide abuse</article-title>. <source>Brain Behav.</source> (<year>2022</year>) <volume>12</volume>:<fpage>e2533</fpage>. <pub-id pub-id-type="doi">10.1002/brb3.2533</pub-id><pub-id pub-id-type="pmid">35307992</pub-id></citation></ref>
<ref id="B8">
<label>8.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>Y</given-names></name> <name><surname>Dong</surname> <given-names>J</given-names></name> <name><surname>Xu</surname> <given-names>R</given-names></name> <name><surname>Feng</surname> <given-names>F</given-names></name> <name><surname>Kan</surname> <given-names>W</given-names></name> <name><surname>Ding</surname> <given-names>H</given-names></name> <etal/></person-group>. <article-title>Clinical epidemiological characteristics of nitrous oxide abusers: a single-center experience in a hospital in China</article-title>. <source>Brain Behav.</source> (<year>2021</year>) <volume>11</volume>:<fpage>e2416</fpage>. <pub-id pub-id-type="doi">10.1002/brb3.2416</pub-id><pub-id pub-id-type="pmid">34775689</pub-id></citation></ref>
<ref id="B9">
<label>9.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beal</surname> <given-names>JC</given-names></name> <name><surname>Cheng</surname> <given-names>Y</given-names></name> <name><surname>Merchant</surname> <given-names>S</given-names></name> <name><surname>Zarnegar</surname> <given-names>R</given-names></name></person-group>. <article-title>An acute, severe axonal sensorimotor polyneuropathy in the setting of nitrous oxide abuse</article-title>. <source>Neurohospitalist.</source> (<year>2020</year>) <volume>10</volume>:<fpage>293</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1177/1941874420910648</pub-id><pub-id pub-id-type="pmid">32983349</pub-id></citation></ref>
<ref id="B10">
<label>10.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>Y</given-names></name> <name><surname>Zhang</surname> <given-names>X</given-names></name> <name><surname>Zhao</surname> <given-names>C</given-names></name></person-group>. <article-title>Electrophysiological characteristics of patients with nitrous oxide abuse</article-title>. <source>Neurol Res.</source> (<year>2021</year>) <volume>43</volume>:<fpage>793</fpage>&#x02013;<lpage>801</lpage>. <pub-id pub-id-type="doi">10.1080/01616412.2021.1935101</pub-id><pub-id pub-id-type="pmid">34101535</pub-id></citation></ref>
<ref id="B11">
<label>11.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname> <given-names>J</given-names></name> <name><surname>Shang</surname> <given-names>X</given-names></name> <name><surname>Wang</surname> <given-names>X</given-names></name> <name><surname>Chen</surname> <given-names>H</given-names></name> <name><surname>Li</surname> <given-names>W</given-names></name> <name><surname>Wang</surname> <given-names>Y</given-names></name> <etal/></person-group>. <article-title>Nitrous oxide-related neurological disorders: clinical, laboratory, neuroimaging, and electrophysiological findings</article-title>. <source>Brain Behav.</source> (<year>2021</year>) <volume>11</volume>:<fpage>e2402</fpage>. <pub-id pub-id-type="doi">10.1002/brb3.2402</pub-id><pub-id pub-id-type="pmid">34758196</pub-id></citation></ref>
<ref id="B12">
<label>12.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berling</surname> <given-names>E</given-names></name> <name><surname>Fargeot</surname> <given-names>G</given-names></name> <name><surname>Aure</surname> <given-names>K</given-names></name> <name><surname>Tran</surname> <given-names>TH</given-names></name> <name><surname>Kubis</surname> <given-names>N</given-names></name> <name><surname>Lozeron</surname> <given-names>P</given-names></name> <etal/></person-group>. <article-title>Nitrous oxide-induced predominantly motor neuropathies: a follow-up study</article-title>. <source>J Neurol.</source> (<year>2022</year>) <volume>269</volume>:<fpage>2720</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1007/s00415-021-10858-2</pub-id><pub-id pub-id-type="pmid">34741241</pub-id></citation></ref>
<ref id="B13">
<label>13.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>McGonigal</surname> <given-names>R</given-names></name> <name><surname>Campbell</surname> <given-names>CI</given-names></name> <name><surname>Barrie</surname> <given-names>JA</given-names></name> <name><surname>Yao</surname> <given-names>D</given-names></name> <name><surname>Cunningham</surname> <given-names>ME</given-names></name> <name><surname>Crawford</surname> <given-names>CL</given-names></name> <etal/></person-group>. <article-title>Schwann cell nodal membrane disruption triggers bystander axonal degeneration in a Guillain-Barr&#x000E9; syndrome mouse model</article-title>. <source>J Clin Investig</source>. (<year>2022</year>) <volume>132</volume>:<fpage>e158524</fpage>. <pub-id pub-id-type="doi">10.1172/JCI158524</pub-id><pub-id pub-id-type="pmid">35671105</pub-id></citation></ref>
<ref id="B14">
<label>14.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yanaka</surname> <given-names>S</given-names></name> <name><surname>Yogo</surname> <given-names>R</given-names></name> <name><surname>Watanabe</surname> <given-names>H</given-names></name> <name><surname>Taniguchi</surname> <given-names>Y</given-names></name> <name><surname>Satoh</surname> <given-names>T</given-names></name> <name><surname>Komura</surname> <given-names>N</given-names></name> <etal/></person-group>. <article-title>On-membrane dynamic interplay between anti-GM1 IgG antibodies and complement component C1q</article-title>. <source>Int J Mol Sci</source>. (<year>2019</year>) <volume>21</volume>:<fpage>147</fpage>. <pub-id pub-id-type="doi">10.3390/ijms21010147</pub-id><pub-id pub-id-type="pmid">31878295</pub-id></citation></ref>
<ref id="B15">
<label>15.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oktar</surname> <given-names>A&#x000C7;</given-names></name> <name><surname>Sel&#x000E7;uk</surname> <given-names>&#x000D6;</given-names></name> <name><surname>Tun&#x000E7;</surname> <given-names>C</given-names></name> <name><surname>I&#x0015F;ildak</surname> <given-names>S</given-names></name> <name><surname>Sanli</surname> <given-names>E</given-names></name> <name><surname>Yilmaz</surname> <given-names>V</given-names></name> <etal/></person-group>. <article-title>Serum anti-ganglioside antibodies in patients with autoimmune limbic encephalitis</article-title>. <source>Turk J Med Sci.</source> (<year>2021</year>) <volume>51</volume>:<fpage>2570</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.3906/sag-2101-348</pub-id><pub-id pub-id-type="pmid">34174799</pub-id></citation></ref>
<ref id="B16">
<label>16.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mohsenzadegan</surname> <given-names>M</given-names></name> <name><surname>Kourosh Arami</surname> <given-names>M</given-names></name> <name><surname>Oshaghi</surname> <given-names>M</given-names></name> <name><surname>Sedigh Maroufi</surname> <given-names>S</given-names></name></person-group>. <article-title>A. review of the effects of the anesthetic gas nitrous oxide on the immune system; a starting point for future experiences</article-title>. <source>Immunopharmacol Immunotoxicol.</source> (<year>2020</year>) <volume>42</volume>:<fpage>179</fpage>&#x02013;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1080/08923973.2020.1735412</pub-id><pub-id pub-id-type="pmid">32131654</pub-id></citation></ref>
</ref-list>
</back>
</article>